Expert Advocates Moving Up Immunotherapy in MSI-H Gastric Cancer

Brittany Lovely
Published: Monday, Feb 03, 2020
Yelena Y.
Janjigian, MD

Yelena Y. Janjigian, MD

Modest activity has been observed with anti–PD-1 therapies for patients with gastric, esophageal, and hepatocellular carcinoma (HCC) in later lines of therapy, but for patients with microsatellite instability–high (MSI-H) tumors and other subgroups, treatment with these agents has shown benefit over chemotherapy in the first-line setting, according to recent data.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication